Search

Your search keyword '"Sestili, Simona"' showing total 39 results
Start Over Author "Sestili, Simona" Publication Type Academic Journals
39 results on '"Sestili, Simona"'

4. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies

Author

Duléry, Rémy, Goudet, Claire, Mannina, Daniele, Bianchessi, Antonio, Granata, Angela, Harbi, Samia, Maisano, Valerio, Chabannon, Christian, Malard, Florent, Brissot, Eolia, Sestili, Simona, Banet, Anne, Van de Wyngaert, Zoé, Belhocine, Ramdane, Ederhy, Stéphane, Castagna, Luca, Bramanti, Stefania, Blaise, Didier, Mohty, Mohamad, Fürst, Sabine, and Devillier, Raynier

Published
2023
Full Text
View/download PDF

5. Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation

Author

Banet, Anne, Bazarbachi, Ali, Labopin, Myriam, Stocker, Nicolas, Duléry, Rémy, Malard, Florent, Van de Wyngaert, Zoé, Genthon, Alexis, Memoli, Mara, Legrand, Ollivier, Bonnin, Agnes, Ledraa, Tounes, Belhocine, Ramdane, Sestili, Simona, El-Cheikh, Jean, Mohty, Mohamad, and Brissot, Eolia

Published
2023
Full Text
View/download PDF

7. Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation

Author

Duléry, Rémy, Mohty, Razan, Labopin, Myriam, Sestili, Simona, Malard, Florent, Brissot, Eolia, Battipaglia, Giorgia, Médiavilla, Clémence, Banet, Anne, Van de Wyngaert, Zoé, Paviglianiti, Annalisa, Belhocine, Ramdane, Isnard, Françoise, Lapusan, Simona, Adaeva, Rosa, Vekhoff, Anne, Ledraa, Tounes, Legrand, Ollivier, Cohen, Ariel, Bonnin, Agnès, Ederhy, Stéphane, and Mohty, Mohamad

Published
2021
Full Text
View/download PDF

8. Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation

Author

Marini, Carolina, Brissot, Eolia, Bazarbachi, Abdulhamid, Duléry, Rémy, Sestili, Simona, Battipaglia, Giorgia, Médiavilla, Clémence, Paviglianiti, Annalisa, Belhocine, Ramdane, Isnard, Francoise, Lapusan, Simona, Adaeva, Rosa, Bannet, Anne, van de Wiegert, Zoé, Vekhoff, Anne, Ledraa, Tounes, Legrand, Ollivier, Labopin, Myriam, Bonnin, Agnes, Ruggeri, Annalisa, Malard, Florent, and Mohty, Mohamad

Published
2020
Full Text
View/download PDF

9. Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies

Author

Peric, Zinaida, Mohty, Razan, Bastos, Juliana, Brissot, Eolia, Battipaglia, Giorgia, Belhocine, Ramdane, Sestili, Simona, Giannotti, Federica, Vekhoff, Anne, Ledraa, Tounes, Legrand, Ollivier, Lapusan, Simona, Isnard, Francoise, Labopin, Myriam, Bonnin, Agnes, Mediavilla, Clemence, Rubio, Marie-Thérèse, Ruggeri, Annalisa, Duléry, Rémy, Malard, Florent, and Mohty, Mohamad

Published
2020
Full Text
View/download PDF

10. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation

Author

Duléry, Rémy, Bastos, Juliana, Paviglianiti, Annalisa, Malard, Florent, Brissot, Eolia, Battipaglia, Giorgia, Médiavilla, Clémence, Giannotti, Federica, Banet, Anne, de Wyngaert, Zoé Van, Ledraa, Tounes, Belhocine, Ramdane, Sestili, Simona, Adaeva, Rosa, Lapusan, Simona, Isnard, Françoise, Legrand, Ollivier, Vekhoff, Anne, Rubio, Marie-Thérèse, Ruggeri, Annalisa, and Mohty, Mohamad

Published
2019
Full Text
View/download PDF

11. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors

Author

Duléry, Rémy, Ménard, Anne-Lise, Chantepie, Sylvain, El-Cheikh, Jean, François, Sylvie, Delage, Jérémy, Giannotti, Federica, Ruggeri, Annalisa, Brissot, Eolia, Battipaglia, Giorgia, Malard, Florent, Belhocine, Ramdane, Sestili, Simona, Vekhoff, Anne, Delhommeau, François, Reman, Oumédaly, Legrand, Ollivier, Labopin, Myriam, Rubio, Marie-Thérèse, and Mohty, Mohamad

Published
2018
Full Text
View/download PDF

12. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study

Author

Bertolotti, Marco, Franchi, Carlotta, Rocchi, Marco B. L., Miceli, Andrea, Libbra, M. Vittoria, Nobili, Alessandro, Lancellotti, Giulia, Carulli, Lucia, Mussi, Chiara, Mannucci, Pier Mannuccio, Nobili, Alessandro, Tettamanti, Mauro, Pasina, Luca, Franchi, Carlotta, Perticone, Francesco, Salerno, Francesco, Corrao, Salvatore, Marengoni, Alessandra, Licata, Giuseppe, Violi, Francesco, Corazza, Gino Roberto, Marcucci, Maura, Eldin, Tarek Kamal, Di Blanca, Maria Pia Donatella, Lanzo, Giovanna, Astuto, Sarah, Tettamanti, Mauro, Ardoino, Ilaria, Cortesi, Laura, Prisco, Domenico, Silvestri, Elena, Cenci, Caterina, Emmi, Giacomo, Biolo, Gianni, Guarnieri, Gianfranco, Zanetti, Michela, Fernandes, Giovanni, Chiuch, Massimiliano, Vanoli, Massimo, Grignani, Giulia, Casella, Gianluca, Pulixi, Edoardo Alessandro, Bernardi, Mauro, Bassi, Silvia Li, Santi, Luca, Zaccherini, Giacomo, Mannarino, Elmo, Lupattelli, Graziana, Bianconi, Vanessa, Paciullo, Francesco, Nuti, Ranuccio, Valenti, Roberto, Ruvio, Martina, Cappelli, Silvia, Palazzuoli, Alberto, Salvatore, Teresa, Sasso, Ferdinando Carlo, Girelli, Domenico, Olivieri, Oliviero, Matteazzi, Thomas, Barbagallo, Mario, Plances, Lidia, Alcamo, Roberta, Licata, Giuseppe, Calvo, Luigi, Valenti, Maria, Pasini, Franco Laghi, Capecchi, Pier Leopoldo, Bicchi, Maurizio, Palasciano, Giuseppe, Modeo, Maria Ester, Peragine, Maria, Pappagallo, Fabrizio, Pugliese, Stefania, Di Gennaro, Carla, Postiglione, Alfredo, Barbella, Maria Rosaria, De Stefano, Francesco, Cappellini, Maria Domenica, Fabio, Giovanna, Seghezzi, Sonia, De Amicis, Margherita Migone, Mancarella, Marta, Mari, Daniela, Rossi, Paolo Dionigi, Damanti, Sarah, Ottolini, Barbara Brignolo, Bonini, Giulia, Corazza, Gino Roberto, Miceli, Emanuela, Lenti, Marco Vincenzo, Padula, Donatella, Murialdo, Giovanni, Marra, Alessio, Cattaneo, Federico, Secchi, Maria Beatrice, Ghelfi, Davide, Anastasio, Luigi, Sofia, Lucia, Carbone, Maria, Davì, Giovanni, Guagnano, Maria Teresa, Sestili, Simona, Mancuso, Gerardo, Calipari, Daniela, Bartone, Mosè, Meroni, Maria Rachele, Perin, Paolo Cavallo, Lorenzati, Bartolomeo, Gruden, Gabriella, Bruno, Graziella, Amione, Cristina, Fornengo, Paolo, Tassara, Rodolfo, Melis, Deborah, Rebella, Lara, Delitala, Giuseppe, Pretti, Vincenzo, Masala, Maristella Salvatora, Pes, Chiara, Bolondi, Luigi, Rasciti, Leonardo, Serio, Ilaria, Fanelli, Filippo Rossi, Amoroso, Antonio, Molfino, Alessio, Petrillo, Enrico, Zuccalà, Giuseppe, Franceschi, Francesco, De Marco, Guido, Chiara, Cordischi, Marta, Sabbatini, D’Aurizio, Gabriella, Romanelli, Giuseppe, Amolini, Claudia, Chiesa, Deborah, Marengoni, Alessandra, Picardi, Antonio, Gentilucci, Umberto Vespasiani, Gallo, Paolo, Annoni, Giorgio, Corsi, Maurizio, Zazzetta, Sara, Bellelli, Giuseppe, Szabo, Hajnalka, Arturi, Franco, Succurro, Elena, Rubino, Mariangela, Sesti, Giorgio, Loria, Paola, Becchi, Maria Angela, Martucci, Gianfranco, Fantuzzi, Alessandra, Maurantonio, Mauro, Serra, Maria Grazia, Bleve, Maria Antonietta, Gasbarrone, Laura, Sajeva, Maria Rosaria, Brucato, Antonio, Ghidoni, Silvia, Di Corato, Paola, Agnelli, Giancarlo, Marchesini, Emanuela, Fabris, Fabrizio, Carlon, Michela, Turatto, Francesca, Baritusso, Aldo, Turatto, Francesca, Amabile, Annalisa, Omenetto, Elisabetta, Scarinzi, Paolo, Manfredini, Roberto, Molino, Christian, Pala, Marco, Fabbian, Fabio, Boari, Benedetta, De Giorgi, Alfredo, Paolisso, Giuseppe, Rizzo, Maria Rosaria, Laieta, Maria Teresa, Rini, Giovanbattista, Mansueto, Pasquale, Pepe, Ilenia, Borghi, Claudio, Strocchi, Enrico, De Sando, Valeria, Pareo, Ilaria, Sabbà, Carlo, Vella, Francesco Saverio, Suppressa, Patrizia, Valerio, Raffaella, Agosti, Pasquale, Fontana, Flavia, Loparco, Francesca, Pugliese, Stefania, Capobianco, Caterina, Fenoglio, Luigi, Bracco, Christian, Giraudo, Alessia Valentina, Testa, Elisa, Serraino, Cristina, Fargion, Silvia, Bonara, Paola, Periti, Giulia, Porzio, Marianna, Tiraboschi, Slivia, Peyvandi, Flora, Tedeschi, Alberto, Rossio, Raffaella, Ferrari, Barbara, Monzani, Valter, Savojardo, Valeria, Folli, Christian, Salerno, Maria Magnini Francesco, Conca, Alessio, Gobbo, Giulia, Conca, Alessio, Pallini, Giada, Valenti, Miriam, Balduini, Carlo L., Bertolino, Giampiera, Provini, Stella, Quaglia, Federica, Dallegri, Franco, Ottonello, Luciano, Liberale, Luca, Chin, Wu Sheng, Carassale, Laura, Caporotundo, Silvia, Traisci, Giancarlo, De Feudis, Lucrezia, Di Carlo, Silvia, Liberato, Nicola Lucio, Buratti, Alberto, Tognin, Tiziana, Bianchi, Giovanni Battista, Giaquinto, Sabrina, Purrello, Francesco, Di Pino, Antonino, Piro, Salvatore, Rozzini, Renzo, Falanga, Lina, Spazzini, Elena, Montrucchio, Giuseppe, Greco, Elisabetta, Tizzani, Pietro, Petitti, Paolo, Perciccante, Antonio, Coralli, Alessia, Salmi, Raffaella, Gaudenzi, Piergiorgio, Gamberini, Susanna, Semplicini, Andrea, Gottardo, Lucia, Vendemiale, Gianluigi, Serviddio, Gaetano, Forlano, Roberta, Masala, Cesare, Mammarella, Antonio, Raparelli, Valeria, Violi, Francesco, Basili, Stefania, Perri, Ludovica, Landolfi, Raffaele, Montalto, Massimo, Mirijello, Antonio, Vallone, Carla, Bellusci, Martino, Setti, Donatella, Pedrazzoli, Filippo, Guasti, Luigina, Castiglioni, Luana, Maresca, Andrea, Squizzato, Alessandro, Molaro, Marta, Bertolotti, Marco, Mussi, Chiara, Libbra, Maria Vittoria, Miceli, Andrea, Pellegrini, Elisa, Carulli, Lucia, Veltri, Francesca, Perticone, Francesco, Sciacqua, Angela, Quero, Michele, Bagnato, Chiara, Colangelo, Lidia, Falbo, Tania, De Giorgio, Roberto, Serra, Mauro, Grasso, Valentina, Ruggeri, Eugenio, Ilaria, Benzoni, Salvi, Andrea, Leonardi, Roberto, Grassini, Chiara, Mascherona, Ilenia, Minelli, Giorgio, Maltese, Francesca, Damiani, Giampaolo, Capeci, William, Mattioli, Massimo, Martino, Giuseppe Pio, Biondi, Lorenzo, Ormas, Monica, Pettinari, Pietro, Romiti, Roberto, Corrao, Salvatore, Messina, Silvia, Cavallaro, Federica, Ghio, Riccardi, Favorini, Serena, Col, Anna Dal, Minisola, Salvatore, Colangelo, Luciano, Afeltra, Antonella, Alemanno, Pamela, Marigliano, Benedetta, Pipita, Maria Elena, Castellino, Pietro, Blanco, Julien, Zanoli, Luca, Cattaneo, Marco, Fracasso, Paola, Amoruso, Maria Valentina, Saracco, Valter, Fogliati, Marisa, Bussolino, Carlo, Durante, Vittorio, Eusebi, Giovanna, Tirotta, Daniela, Mete, Francesca, Gino, Miriam, Cittadini, Antonio, Vigorito, Carlo, Arcopinto, Michele, Salzano, Andrea, Bobbio, Emanuele, Marra, Alberto Maria, Sirico, Domenico, Moreo, Guido, Scopelliti, Francesco, Gasparini, Francesca, Cocca, Melissa, Ballestrero, Alberto, Ferrando, Fabio, Berra, Sergio, Dassi, Simonetta, Nava, Maria Cristina, Graziella, Bruno, Ghidoni, Silvia, Amione, Cristina, Baldassarre, Stefano, Fragapani, Salvatore, Gruden, Gabriella, Galanti, Giorgio, Mascherini, Gabriele, Petri, Cristian, Stefani, Laura, Girino, Margherita, Piccinelli, Valeria, Nasso, Francesco, Gioffrè, Vincenza, Pasquale, Maria, Scattolin, Giuseppe, Martinelli, Sergio, Turrin, Mauro, Sechi, Leonardo, Catena, Cristina, Colussi, Gianluca, Nieves, Ramirez Duque, Alberto, Muela Molinero, Pedro, Abad Requejo, Vanessa, Lopez Pelaez, Lara, Tamargo, Xavier, Corbella Viros, Francesc, Formiga, Jesus, Diez Manglano, Esperanza, Bejarano Tello, Esther, Del Corral Behamonte, Maria, Sevil Puras, Romero, Manuel, Blanca, Pinilla Llorente, Cristina, Lopez Gonzalez-Cobos, Victoria, Villalba Garcia M., Saez, Lopez, Bosco, Juan, Susana, Sanz Baena, Marta, Arroyo Gallego, Concepcion, Gonzalez Becerra, Antonio, Fernandez Moyano, Hernandez, Mercedes Gomez, Borrego, Manuel Poyato, Raquel, Pacheco Cuadros, Florencia, Perez Rojas, Beatriz, Garcia Olid, Sara, Carrascosa Garcia, Alfonso, Gonzalez-Cruz Cervellera, Marta, Peinado Martinez, Garcia, Sara Carrascosa, Alberto, Ruiz Cantero, Antonio, Albarracín Arraigosa, Montserrat, Godoy Guerrero, Ángel, Barón Ramos Miguel, Manuel, Machin Jose, Ignacio, Novo Veleiro, Lucía, Alvela Suarez, Alfonso, Lopez, David, Rubal Bran, Iria, Iñiguez Vazquez, Monica, Rios Prego, and On behalf of REPOSI Investigators

Published
2017
Full Text
View/download PDF

14. Pulmonary Alveolar Proteinosis After Allogeneic Hematopoietic Stem-Cell Transplantation in Adults: A French Société Francophone de Greffe de Moelle et Thérapie Cellulaire Survey

Author

Salvator, Helene, Tcherakian, Colas, Maillard, Natacha, Milin, Serge, Bergeron, Anne, Bondeelle, Louise, Meignin, Veronique, Nguyen, Stephanie, Souchet, Laetitia, Guenounou, Sarah, Evrard, Solène M., Rubio, Marie-Therese, Robin, Marie, Sestili, Simona, Brissot, Eolia, Fajac, Anne, Catherinot, Emilie, Givel, Claire, Chabrol, Alexandre, Goyard, Céline, Longchampt, Elisabeth, Chabi-Charvillat, Marie-Laure, Bernaudin, Jean-Francois, and Couderc, Louis-Jean

Published
2021
Full Text
View/download PDF

16. Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.

Author

Genthon, Alexis, Dragoi, Diana, Memoli, Mara, Hirsch, Pierre, Favale, Fabrizia, Suner, Ludovic, Chaquin, Michael, Boncoeur, Pierre, Marjanovic, Zora, Bonnin, Agnès, Sestili, Simona, Dulery, Remy, Malard, Florent, Brissot, Eolia, Banet, Anne, van de Wyngaert, Zoe, Vekhoff, Anne, Delhommeau, Francois, Mohty, Mohamad, and Legrand, Ollivier

Subjects
ACUTE myeloid leukemia, ISOCITRATE dehydrogenase, AZACITIDINE, STEM cell transplantation, FLUDARABINE
Abstract

Patients received a median of one line of treatment (range, 1-4) prior to IDHi therapy and three patients had already received a first allo-SCT. No patients received IDHi as maintenance therapy after allo-SCT; four patients received a prophylactic treatment with azacitidine. There were no treatment-related deaths (one patient, treated with ivosidenib, developed a differentiation syndrome which evolved favourably after appropriate treatment and three patients developed a grade III-IV infection during IDHi treatment). Five patients had sequential conditioning (chemotherapy with broad antitumour activity followed by reduced-intensity conditioning regimen) and two patients had reduced-intensity conditioning.12 All patients had a haploidentical donor. [Extracted from the article]

Published
2022
Full Text
View/download PDF

17. Low incidence of hyperacute graft‐versus‐host disease (GVHD) with effective GVHD prophylaxis based on anti‐thymocyte globulin.

Author

Radici, Vera, Stocker, Nicolas, Dulery, Rémy, Brissot, Eolia, Bannet, Anne, van de Wyngaert, Zoe, Sestili, Simona, Belhocine, Ramdane, Bonin, Agnes, Ledraa, Tounes, Mohty, Mohamad, and Malard, Florent

Subjects
GRAFT versus host disease, ACUTE diseases, GLOBULINS
Abstract

While there was no difference in the incidence of severe Stage 3-4 skin aGVHD between patients with haGVHD versus others (46% vs. 30%, I p i = 0.2), severe Stage 3-4 liver and gastrointestinal aGVHD were more frequent in patients with haGVHD (38% vs. 18%, I p i = 0.015; and 15% vs. 4%, I p i = 0.0002 respectively). (C) Cumulative incidence of severe National Institutes of Health (NIH) Stage 2-3 chronic GVHD gl Overall, we found a low incidence of haGVHD in our cohort, only 10.4% of patients with Grade II-IV aGVHD leading to a day 14 cumulative incidence of 2.7%. OS was comparable between patients with Grade II-IV haGVHD (53.9%, 95% CI 24.8%-76.0%) and patients with Grade II-IV aGVHD after day 14 (45.7%, 95% CI 35.4%-55.4%, I p i = 0.23) (Figure 1A). [Extracted from the article]

Published
2022
Full Text
View/download PDF

19. Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience.

Author

Paviglianiti, Annalisa, Sestili, Simona, Bianchessi, Antonio, Memoli, Mara, Dulery, Remy, Banet, Anne, Van De Wyngaert, Zoe, Belhocine, Ramdane, Ledraa, Tounes, Malard, Florent, Mohty, Mohamad, and Brissot, Eolia

Subjects
*STEM cell transplantation, *HEMATOPOIETIC stem cell transplantation, *PULMONARY function tests, *BRONCHIOLITIS, *LUNG volume measurements, *CYCLOPHOSPHAMIDE, *INTERSTITIAL lung diseases
Abstract

Prior studies have reported pulmonary function tests (PFT) before and after related and unrelated allogeneic hematopoietic stem cell transplantation (HSCT). However, limited data exist on the evaluation of lung function after haploidentical stem cell transplantation (HAPLO) with post-transplant cyclophosphamide (PTCY). We retrospectively reported the evaluation of PFTs at screening before HAPLO in 80 patients at 100 days and 1 year of follow-up. The proportion of surviving patients with available PFTs at 100 days and 1 year were 86% and 68%, respectively. During the follow-up period, four patients met the criteria for bronchiolitis obliterans syndrome and two for interstitial lung disease. Overall survival was 73% (95% CI 62–82%) at 2 years. We observed a significant reduction in diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for the most recent hemoglobin concentration (DLCOc) at 100 days after HAPLO. However, an overall substantial stable pulmonary function was observed at 1 year. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.

Author

Memoli, Mara, Paviglianiti, Annalisa, Malard, Florent, Battipaglia, Giorgia, Brissot, Eolia, Médiavilla, Clémence, Bianchessi, Antonio, Banet, Anne, Van de Wyngaert, Zoé, Ledraa, Tounes, Belhocine, Ramdane, Sestili, Simona, Lapusan, Simona, Hirsch, Pierre, Favale, Fabrizia, Boussaroque, Agathe, Bonnin, Agnès, Vekhoff, Anne, Legrand, Ollivier, and Mohty, Mohamad

Subjects
TOTAL body irradiation, MYELOFIBROSIS, GRAFT versus host disease, BUSULFAN, STEM cells, BLOOD cells
Abstract

We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42–70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II–IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10–42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23–65) at 3 years. The median follow-up period was 39 (range 14–60) months. Overall survival was 69% (95% CI, 50–83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation.

Author

Genthon, Alexis, Brissot, Eolia, Malard, Florent, van de Wyngaert, Zoe, Bonnin, Agnès, Banet, Anne, Marjanovic, Zora, Ikhlef, Souhila, Lapusan, Simona, Sestili, Simona, Corre, Elise, Paviglianiti, Annalisa, Adaeva, Rosa, 'Hammedi-Bouzina, Fella M., Labopin, Myriam, Dulery, Rémy, Mohty, Mohamad, and Legrand, Ollivier

Published
2020
Full Text
View/download PDF

23. High‐dose post‐transplant cyclophosphamide impairs γδ T‐cell reconstitution after haploidentical haematopoietic stem cell transplantation using low‐dose antithymocyte globulin and peripheral blood stem cell graft.

Author

Stocker, Nicolas, Gaugler, Béatrice, Labopin, Myriam, Farge, Agathe, Ye, Yishan, Ricard, Laure, Brissot, Eolia, Duléry, Remy, Sestili, Simona, Battipaglia, Giorgia, Médiavilla, Clémence, Paviglianiti, Annalisa, Banet, Anne, Van De Wyngaert, Zoe, Ledraa, Tounes, Mohty, Mohamad, and Malard, Florent

Subjects
STEM cell transplantation, STEM cells, BLOOD cells, CELL transplantation, T cells
Abstract

Objectives: Haploidentical haematopoietic cell transplantation (Haplo‐HCT) using peripheral blood stem cell (PBSC) grafts and post‐transplant cyclophosphamide (PTCy) is being increasingly used; however, data on immunological reconstitution (IR) are still scarce. Methods: This retrospective study evaluated T‐cell immunological reconstitution in 106 adult patients who underwent allogeneic haematopoietic cell transplantation for haematologic malignancies between 2013 and 2016. Results: At D30, while conventional T cells reached similar median counts in Haplo‐HCT recipients (n = 19) and controls (n = 87), γδ and Vδ2+ T‐cell median counts were significantly lower in Haplo‐HCT recipients and it persists at least until D360 for Vδ2+ T cells. PTCy induces a significant reduction in early γδ and Vδ2+ T‐cell proliferation at D 7. At one year, the rate of increase in Epstein–Barr virus (EBV) viral load was significantly higher in Haplo‐HCT recipients as compared to controls (61% versus 34%, P = 0.02). In multivariate analysis, a higher γδ T‐cell count (> 4.63 μL−1) at D30 was the only independent parameter significantly associated with a reduced risk of increase in EBV viral load (RR 0.34; 95% CI, 0.15–0.76, P = 0.009). Conclusion: Immunological reconstitution of γδ T cells is significantly delayed after Haplo‐HCT using PTCy and low‐dose ATG and is associated with an increased risk of increase in EBV viral load. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

24. Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience.

Author

Sestili, Simona, Eder, Sandra, Belhocine, Ramdane, Dulery, Remy, Battipaglia, Giorgia, Brissot, Eolia, Mediavilla, Clemence, Banet, Anne, van de Wyngaert, Zoe, Paviglianiti, Annalisa, Ledraa, Tounes, Bonin, Agnes, Mohty, Mohamad, and Malard, Florent

Subjects
*HEMATOPOIETIC stem cell transplantation, *ADRENOCORTICAL hormones, *GRAFT versus host disease, *ACUTE diseases
Abstract

Background aims: Corticosteroids are the standard first-line treatment for acute graft-versus-host disease (aGVHD), but they are associated with many complications, and less than half of patients have a sustained response. Methods: To improve outcomes, we performed a retrospective study to analyze the efficacy of the addition of extracorporeal photopheresis (ECP) to low-dose corticosteroids in 37 adult patients (median age, 57 years) with skin-predominant aGVHD (grade I, n = 17; grade II, n = 18; and grade III, n = 2). All patients received ECP in combination with 1 mg/kg prednisone (n = 26) or topical steroids (n = 11). Results: Overall response rate was 81% after a median of three ECP procedures (range, 2–8), including 22 complete responses (CR, 59%) and eight very good partial responses (VGPR, 22%). The 11 patients treated with topical corticosteroids achieved CR. Furthermore, 16 (62%) patients reached prednisone withdrawal at a median of 100 days (range, 42–174 days) after its initiation. Eighteen patients developed chronic GVHD (cGVHD); 11 of them (who were in CR of aGVHD) had a new-onset cGVHD, and seven experienced progressive cGVHD (five non-responding and two VGPR patients). A second-line immunosuppressive treatment was initiated in only five (14%) non-responding patients. With a median follow-up of 31 months (range, 6–57 months) 2-year overall survival and non-relapse mortality were 74% and 11%, respectively. Conclusions: Overall, the combination of low-dose corticosteroids and ECP appear to be safe and effective for first-line treatment of skin predominant aGVHD. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

26. Infectious complications after post‐transplantation cyclophosphamide and anti‐thymocyte globulin‐based haploidentical stem cell transplantation.

Author

Mohty, Razan, Brissot, Eolia, Battipaglia, Giorgia, Ruggeri, Annalisa, Dulery, Rémy, Bonnin, Agnès, Médiavilla, Clémence, Sestili, Simona, Belhocine, Ramdane, Vekhoff, Anne, Ledraa, Tounes, Lapusan, Camelia Simona, Adaeva, Rosa, Isnard, Françoise, Legrand, Olivier, Mohty, Mohamad, and Malard, Florent

Subjects
STEM cell transplantation, TOTAL body irradiation, HEMATOPOIETIC stem cell transplantation
Abstract

GLO:1XW/01nov19:bjh16189-fig-0001.jpg PHOTO (COLOR): Cumulative incidence of infection-related mortality (A); bacterial infections (B); CMV reactivation (C), EBV reactivation (D), BK virus cystitis (E) and fungal infection (F). Eight patients were admitted to the intensive care unit (ICU) because of a serious and life-threatening bacterial infection, which was lethal in five patients (Data S1). Furthermore, only one of our patients developed CMV disease (CMV retinitis) compared to the 15% incidence of CMV organ disease after PBSC Haplo-HCT with PT-Cy reported by Slade et al ([6]). Overall, although the CI of viral reactivation was relatively high, none of the viral infections required admission to the ICU and only one patient died from viral infection (severe BK virus cystitis). [Extracted from the article]

Published
2019
Full Text
View/download PDF

27. Impact of cyclosporine A concentration on acute graft‐vs‐host disease incidence after haploidentical hematopoietic cell transplantation.

Author

Stocker, Nicolas, Duléry, Remy, Battipaglia, Giorgia, Brissot, Eolia, Médiavilla, Clémence, Sestili, Simona, Paviglianiti, Annalisa, Ledraa, Tounes, Mohty, Razan, Bazarbachi, Abdulhamid, Belhocine, Ramdane, Vekhoff, Anne, Ruggeri, Annalisa, Mohty, Mohamad, and Malard, Florent

Subjects
CELL transplantation, ACUTE diseases, DISEASE incidence, PROGRESSION-free survival, STEM cell transplantation
Abstract

Objectives: This retrospective study analyzed the impact of early cyclosporine A (CsA) initiation (day −3) on the risk of acute graft‐vs‐host disease (aGvHD) after haploidentical hematopoietic cell transplantation (Haplo‐HCT) using post‐transplant cyclophosphamide. Methods: Sixty‐one consecutives patients who underwent Haplo‐HCT were analyzed. Results: At day +180, the cumulative incidences of grade II‐IV and grade III‐IV aGvHD were 39% and 18%, respectively. Patients having a lowest CsA concentration (<301 ng/mL; the cutoff value used to segregate the patients between low and high CsA concentrations) in the first week after Haplo‐HCT had a significantly higher risk of grade II‐IV aGvHD (P = 0.02), severe grade III‐IV aGvHD (P = 0.03), cGvHD (P = 0.02), and extensive cGvHD (P = 0.04). In multivariate analysis, a higher CsA concentration (≥301 ng/mL) during the first week following Haplo‐HCT was the only parameter significantly associated with a reduced risk of grade II‐IV and grade III‐IV aGvHD (RR = 0.21; P = 0.049 and RR < 0.001; P < 0.0001, respectively). We find no correlation between CsA concentration and relapse, non‐relapse mortality, progression‐free survival, GvHD‐free and progression‐free survival, or overall survival. Conclusions: CsA could be initiated early before Haplo‐HCT with achievement of high CsA concentration to reduce the risk of aGvHD without any detrimental effect on relapse. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

30. A Delayed Innate T Cell Reconstitution Is Associated with Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation Using Anti-Thymoglobulin and High-Dose Post-Transplant Cyclophosphamide

Author

Stocker, Nicolas, Farge, Agathe, Ricard, Laure, Jachiet, Vincent, Mediavilla, Clemence, Brissot, Eolia, Battipaglia, Giorgia, Duléry, Remy, Sestili, Simona, Ruggeri, Annalisa, Mohty, Razan, Mohty, Mohamad, Gaugler, Béatrice, and Malard, Florent

Published
2018
Full Text
View/download PDF

31. T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT).

Author

Sestili, Simona, Labopin, Myriam, Ruggeri, Annalisa, Velardi, Andrea, Ciceri, Fabio, Maertens, Johan, Kanz, Lothar, Aversa, Franco, Lewalle, Philippe, Bunjes, Donald, Mohty, Mohamad, and Nagler, Arnon

Subjects
*ACUTE leukemia, *HLA histocompatibility antigens, *STEM cell transplantation, *T cells, *PATIENTS, *LEUKEMIA treatment
Abstract

Background: T-cell-depleted, haploidentical transplantations (haplos) are commonly offered to patients who have high-risk, acute leukemia in the absence of a human leukocyte antigen (HLA) full-matched donor.Methods: To determine the effect of transplantation period, the authors divided 308 adults with de novo, acute leukemia who underwent T-cell-depleted haplo from 2005 to 2015 into 2 groups, according the year in which they underwent transplantation (2005-2011 [n = 191] and 2012-2015 [n = 117]).Results: The median age was 41 years in patients who underwent transplantation before 2012 and 46 years in those who underwent transplantation after 2012 (P = .04). Most patients had acute myeloid leukemia (75% vs 69%; P = .26) and were in first complete remission (CR1) (55% vs 64%; P = .12) at the time of transplantation. The cumulative incidence of grade 2, 3, and 4 acute graft-versus-host disease (GvHD) and chronic GvHD were not different between the 2 groups (acute GvHD: 20% vs 22% cumulative incidence in patients who underwent haplo before and after 2012, respectively [P = .67]; chronic GvHD: 19% vs 11% cumulative incidence, respectively; P = .12]. The 2-year relapse incidence was 20%, the nonrelapse mortality (NRM) rate was 48%, and no difference was observed over time (21% vs 19% [P = .72] and 54% vs 38% [P = .11] for patients who underwent haplo before and after 2012, respectively). The main cause of NRM was infection. Haplo after 2012 (hazard ratio [HR], 0.57; P = .01), younger age (HR, 0.82; P = .02), and receipt of a reduced-intensity conditioning (RIC) regimen (HR, 0.53; P = .01) were independently associated with lower NRM. The 2-year overall survival rate was 36% and improved after 2012 (29% vs 47% before 2012; P = .02); and it was higher for patients who underwent transplantation in CR1 (41% vs 29%; P = .01). In multivariate analysis, haplo after 2012 (HR, 0.54; P = .003) and receipt of a RIC regimen (HR, 0.54; P = .005) were independently associated with better overall survival. Similarly, leukemia-free survival and GvHD-free/relapse-free survival (GRFS) improved over time: the leukemia-free survival rate was 31% (25% vs 43% in the groups who underwent transplantation before and after 2012, respectively; P = .05), and the GRFS rate was 24% (19% vs 34%, respectively; P = .09). In addition, leukemia-free survival and GRFS improved among patients who received a RIC regimen.Conclusions: The outcome of patients with acute leukemia who underwent T-cell-depleted haplo has improved over time. Cancer 2018;124:2142-50. © 2018 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

34. Weight Loss in Obese Prepubertal Children: The Influence of Insulin Resistance.

Author

Chiavaroli, Valentina, Giannini, Cosimo, D'Adamo, Ebe, de Giorgis, Tommaso, Torello, Monica, D'Orazio, Nicolantonio, Sestili, Simona, Chiarelli, Francesco, and Mohn, Angelika

Subjects
WEIGHT loss, INSULIN resistance, DIABETES complications, OBESITY, DRUG resistance
Abstract

Background. Insulin resistance (IR), a link of paramount importance between obesity and cardiovascular/metabolic complications, seems to be implicated in weight changes. Objective. To determine whether IR could influence weight status during a 1-year intervention program in obese prepubertal children. Methods. Forty-four children with IR (IR group) and 42 children without IR (NIR group) were enrolled. Body mass index standard deviation score (BMI-SDS), waist circumference (WC), and homeostasis model assessment (HOMA-IR) were evaluated. Results. NIR children showed a significant reduction of BMI-SDS and WC at final assessment ( p = 0.009 and p = 0.001, respectively), whereas IR children presented unchanged values. HOMA-IR decreased after intervention in the NIR group ( p = 0.0008), but was exacerbated in IR children ( p = 0.004). A positive and significant association between HOMA-IR at baseline and BMI at follow-up was found ( B ± SE = 0.87 ± 0.24, p = 0.001). HOMA-IR at baseline was also significantly associated with WC at follow-up ( B ± SE = 2.12 ± 0.69, p = 0.003). Conclusions. IR seems to influence adiposity changes in obese prepubertal children. Further longitudinal studies are needed to verify the relationship between IR and weight loss during childhood. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

36. Variability in the response to antiplatelet treatment in diabetes mellitus

Author

Davì, Giovanni, Vazzana, Natale, and Sestili, Simona

Subjects
*PLATELET aggregation inhibitors, *DIABETES, *BLOOD platelet activation, *ASPIRIN, *PHARMACOKINETICS, *DRUG efficacy, *PHARMACODYNAMICS, *THROMBOSIS
Abstract

Abstract: Atherothrombosis is a leading cause of death in patients with diabetes mellitus. Among factors contributing to the diabetic prothrombotic state, platelet activation plays a pivotal role. Numerous studies have investigated the benefits of antiplatelet therapy for primary and secondary cardiovascular prevention in diabetic patients. However, there are limited evidences that low-dose aspirin may be effective in this clinical setting. Several disease-specific factors have been identified as potential determinants of aspirin treatment failure. In this review, the main determinants of interindividual variability in response to antiplatelet agents are discussed, with particular emphasis on the pharmacokinetic and pharmacodynamic mechanisms of clinical efficacy and safety of antiplatelet drugs in patients with diabetes mellitus. [Copyright &y& Elsevier]

Published
2012
Full Text
View/download PDF

38. Human herpesvirus type 6 reactivation after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide and antithymocyte globulin: risk factors and clinical impact.

Author

Paviglianiti A, Maia T, Gozlan JM, Brissot E, Malard F, Banet A, Van de Wyngaert Z, Ledraa T, Belhocine R, Sestili S, Capes A, Stocker N, Bonnin A, Vekhoff A, Legrand O, Mohty M, and Duléry R

Abstract

Human herpesvirus type 6 (HHV6) reactivation after haploidentical hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PT-Cy) has been scarcely studied, especially when antithymocyte globulin (ATG) is added to the graft-versus-host disease (GvHD) prophylaxis. We conducted a retrospective cohort study in 100 consecutive patients receiving haploidentical HCT with PT-Cy. We systematically monitored HHV6 DNA loads in blood samples on a weekly basis using quantitative PCR until day +100. The 100-day cumulative incidence of HHV6 reactivation was 54%. Clinically significant HHV6 infections were rare (7%), associated with higher HHV6 DNA loads, and had favorable outcomes after antiviral therapy. The main risk factor for HHV6 reactivation was a low absolute lymphocyte count (ALC) \< 290/µL on day +30 (68% versus 40%, p = 0.003). Adding ATG to PT-Cy did not increase the incidence of HHV6 reactivation (52% with ATG versus 79% without ATG, p = 0.12). Patients experiencing HHV6 reactivation demonstrated delayed platelet recovery (HR 1.81, 95% CI 1.07-3.05, p = 0.026), higher risk of acute grade II-IV GvHD (39% versus 9%, p \< 0.001) but similar overall survival and non-relapse mortality to the other patients. In conclusion, our findings endorse the safety of combining ATG and PT-Cy in terms of the risk of HHV6 reactivation and infection in patients undergoing haploidentical HCT. Patients with a low ALC on day +30 face a higher risk of HHV6 reactivation and may require careful monitoring., Competing Interests: FM reports lecture honoraria from Therakos/Mallinckrodt, Sanofi, JAZZ Pharmaceuticals, Gilead, Novartis, and Bristol Myers Squibb, all outside the submitted work. MM reports grants and lecture honoraria from Janssen, Sanofi, Maat Pharma and JAZZ Pharmaceuticals, lecture honoraria from Celgene, Amgen, BMS, Takeda, and Pfizer, grants from Roche, all outside the submitted work. RD reports research funding from Ligue contre le Cancer, Arthur Sachs, Monahan Foundation, Servier Foundation, Philippe Foundation, DCP AP-HP, honoraria from Novartis and Takeda, non-financial support from Kite Pharma / Gilead, all outside the submitted work. The other authors declare no competing financial interests.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results